NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues

DALLAS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares of the company's common stock for approximately $230,510, according to a newly filed SEC Form 4.

The transactions took place on November 5 and 6, with Heshmatpour purchasing 30,000 shares at a weighted average price of approximately $3.17 on the first day and another 40,000 shares at approximately $3.39 on the second. His reported beneficial ownership increased to approximately 7.77 million shares, including holdings through affiliated entities.

This is not an isolated show of confidence. Heshmatpour has repeatedly purchased shares in the open market during 2026, including purchases in August and September. In its November 5 quarterly update, NeOnc disclosed that Heshmatpour and fellow insider Thomas C. Chen had purchased a combined 160,016 shares for approximately $629,000 following the company's positive Phase 2a NEO100 results.

The latest purchases add another $231,000 to that buying pattern and are particularly noteworthy given the company's upcoming clinical catalysts.

NeOnc is developing NEO100, an intranasal treatment candidate for recurrent IDH1-mutant high-grade glioma, and NEO212, an investigational therapy for central nervous system cancers. The company reported in August that its NEO100 Phase 2a study met its primary endpoint, achieving six-month progression-free survival of 48.9%, compared with a prespecified 20% benchmark (p=0.0047).

Updated NEO100 data and NEO212 Phase 1 findings are scheduled for presentation at the Society for Neuro-Oncology annual meeting on November 13.

At InvestorsTape.com, our mission is simple: deliver financial news that cuts through the noise and shines a spotlight on the companies, innovations, and market forces shaping the next decade of growth. In a landscape dominated by high-frequency headlines and fleeting narratives, we bring clarity, depth, and balance to the stories that matter, helping investors discover high-potential companies and evaluate emerging opportunities with confidence.

Contact

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements that may regard NeOnc Technologies Holdings’ future revenue, growth trajectory, profitability outlook, expansion plans, strategic partnerships, potential regulatory approvals, and other projections, plans, and objectives. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including market conditions, timing of venue openings, execution risks, operational performance, competition, regulatory matters, and general economic conditions. Readers should not place undue reliance on these statements, which speak only as of the date made.

InvestorsTape.com has been compensated for press and editorial coverage of NeOnc Technologies Holdings and further disclosure information is available here. This communication is provided for informational and journalistic purposes only and reflects the independent editorial views of InvestorsTape.com.

This editorial discusses investigational therapy and clinical-trial results and is not medical advice or a recommendation to buy or sell securities. This publication is protected speech under the First Amendment of the United States Constitution. Nothing herein constitutes an offer, solicitation, or recommendation to buy or sell any security, nor should it be construed as investment advice. Investing in securities involves risk, including the possible loss of principal. Readers are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decision.